Cost-benefit analysis of risperidone and clozapine in the treatment of schizophrenia in Israel

Gary Ginsberg, Segev Shani, Boaz Lev

Research output: Contribution to journalArticlepeer-review

13 Scopus citations


In this study, the benefits and costs of treating schizophrenia with either risperidone or clozapine were examined. The lifetime drug-treatment cost incurred by a patient with schizophrenia in Israel was $US7561 (1996 values) with an initial 6-month trial with risperidone, compared with $US6326 with clozapine and $US3360 with typical antipsychotics. Total lifetime costs of psychiatric health services (excluding medications) by individuals who were continuously receiving typical antipsychotics were $US 181 555 per patient. Assuming a 6.3% decrease in hospital use with typical antipsychotics and an absolute 30% decrease with risperidone or clozapine, the use of clozapine or risperidone reduced hospitalisation costs by $US7159 per patient, but increased community-care costs by $US1627 per patient, giving health-service benefit: cost ratios of 1.87 : 1 and 1.32 : 1, respectively. After adding indirect benefits resulting from increased work productivity (minus indirect costs related to increases in transport costs because of visits for blood monitoring during clozapine therapy), the benefit : cost ratios increased to 2.04 : 1 and 1.48 : 1, respectively. Assuming that clozapine caused a 30% decrease in hospital use by patients with new-onset schizophrenia, risperidone would have to decrease hospital use by 43.2% (i.e. a 13.2% relative advantage) for its societal benefits to justify its increased costs.

Original languageEnglish
Pages (from-to)231-241
Number of pages11
Issue number2
StatePublished - 1 Jan 1998
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology
  • Health Policy
  • Public Health, Environmental and Occupational Health


Dive into the research topics of 'Cost-benefit analysis of risperidone and clozapine in the treatment of schizophrenia in Israel'. Together they form a unique fingerprint.

Cite this